Haralambos Raftopoulos, MD, associate professor, Hofstra North Shore-LIJ School of Medicine, discusses pulmonary toxicity with EGFR tyrosine kinase inhibitors (TKIs).
Haralambos Raftopoulos, MD
Advertisement
Articles by Haralambos Raftopoulos, MD
Advertisement
Latest Updated Articles
Dr. Raftopoulos on Pulmonary Toxicity With EGFR TKIsJune 26th 2014
Advertisement
Advertisement
Trending on OncLive
1
Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer
2
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC
3
Pembrolizumab Plus Chemo Misses EFS End Point in Cisplatin-Eligible MIBC
4
Ad Hoc Analysis Supports Contributions of Both Enfortumab Vedotin and Pembrolizumab in Cisplatin-Ineligible MIBC
5